# Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent (DTwP-Hib-Hep B) Vaccine in Infants 6-8 Weeks of Age

> **NCT01470287** · PHASE3 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 175 (actual)

## Conditions studied

- Diphtheria
- Tetanus
- Pertussis
- Hepatitis B
- Hemophilus Influenzae B

## Interventions

- **BIOLOGICAL:** DTwP-HepB-Hib Vaccine

## Key facts

- **NCT ID:** NCT01470287
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 175 (ACTUAL)
- **Last updated:** 2017-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01470287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01470287, "Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent (DTwP-Hib-Hep B) Vaccine in Infants 6-8 Weeks of Age". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01470287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*